The Imbalance Between Type 17 T-cells and Regulatory Immune Cell Subsets in Psoriasis Vulgaris

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 16

PMID 36110854

Authors

Jaehwan Kim

Ariana Moreno

James G Krueger

Affiliations

Soon will be listed here.

Abstract

Psoriasis vulgaris is a common inflammatory disease affecting 7.5 million adults just in the US. Previously, psoriasis immunopathogenesis has been viewed as the imbalance between CD4 T-helper 17 (Th17) cells and regulatory T-cells (Tregs). However, current paradigms are rapidly evolving as new technologies to study immune cell subsets in the skin have been advanced. For example, recently minted single-cell RNA sequencing technology has provided the opportunity to compare highly differing transcriptomes of Type 17 T-cell (T17 cell) subsets depending on IL-17A . IL-17F expression. The expression of regulatory cytokines in T17 cell subsets provided evidence of T-cell plasticity between T17 cells and regulatory T-cells (Tregs) in humans. In addition to Tregs, other types of regulatory cells in the skin have been elucidated, including type 1 regulatory T-cells (Tr1 cells) and regulatory dendritic cells. More recently, investigators are attempting to apply single-cell technologies to clinical trials of biologics to test if monoclonal blockade of pathogenic T-cells will induce expansion of regulatory immune cell subsets involved in skin homeostasis.

Citing Articles

S1PR1 mediates Th17 cell migration from the thymus to the skin in health and disease.

Engesser J, Wang H, Kapffer S, Kaffke A, Peters A, Paust H Front Immunol. 2024; 15:1473130.

PMID: 39380990 PMC: 11459589. DOI: 10.3389/fimmu.2024.1473130.

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy.

Blauvelt A, Chen Y, Branigan P, Liu X, DePrimo S, Keyes B JID Innov. 2024; 4(5):100297.

PMID: 39224116 PMC: 11367549. DOI: 10.1016/j.xjidi.2024.100297.

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.

Blauvelt A, Langley R, Branigan P, Liu X, Chen Y, DePrimo S JID Innov. 2024; 4(5):100287.

PMID: 39114670 PMC: 11305298. DOI: 10.1016/j.xjidi.2024.100287.

Antiproliferative and Anti-Inflammatory Effects of the Polyphenols Phloretin and Balsacone C in a Coculture of T Cells and Psoriatic Keratinocytes.

Ruel Y, Moawad F, Alsarraf J, Pichette A, Legault J, Brambilla D Int J Mol Sci. 2024; 25(11).

PMID: 38891824 PMC: 11171971. DOI: 10.3390/ijms25115639.

Knowledge mapping of links between dendritic cells and allergic diseases: A bibliometric analysis (2004-2023).

Meng X, Wang Y, Li Z, Yang F, Wang J Heliyon. 2024; 10(10):e30315.

PMID: 38765036 PMC: 11096944. DOI: 10.1016/j.heliyon.2024.e30315.

References

Rizvi S, Chaudhari K, Syed B . The psoriasis drugs market. Nat Rev Drug Discov. 2015; 14(11):745-6. DOI: 10.1038/nrd4763. View

Lee Y, Awasthi A, Yosef N, Quintana F, Xiao S, Peters A . Induction and molecular signature of pathogenic TH17 cells. Nat Immunol. 2012; 13(10):991-9. PMC: 3459594. DOI: 10.1038/ni.2416. View

Papp K, Blauvelt A, Bukhalo M, Gooderham M, Krueger J, Lacour J . Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017; 376(16):1551-1560. DOI: 10.1056/NEJMoa1607017. View

Kim J, Bissonnette R, Lee J, Da Rosa J, Suarez-Farinas M, Lowes M . The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. J Invest Dermatol. 2016; 136(11):2173-2182. DOI: 10.1016/j.jid.2016.04.032. View

Peternel S, Kastelan M . Immunopathogenesis of psoriasis: focus on natural killer T cells. J Eur Acad Dermatol Venereol. 2009; 23(10):1123-7. DOI: 10.1111/j.1468-3083.2009.03292.x. View

Chung Y, Yamazaki T, Kim B, Zhang Y, Reynolds J, Martinez G . Epstein Barr virus-induced 3 (EBI3) together with IL-12 negatively regulates T helper 17-mediated immunity to Listeria monocytogenes infection. PLoS Pathog. 2013; 9(9):e1003628. PMC: 3777861. DOI: 10.1371/journal.ppat.1003628. View

Ostroumov D, Duong S, Wingerath J, Woller N, Manns M, Timrott K . Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. Hepatology. 2020; 73(4):1399-1418. DOI: 10.1002/hep.31466. View

Gordon K, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B . Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2017; 178(1):132-139. DOI: 10.1111/bjd.16008. View

Cheuk S, Wiken M, Blomqvist L, Nylen S, Talme T, Stahle M . Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014; 192(7):3111-20. PMC: 3962894. DOI: 10.4049/jimmunol.1302313. View

10.

Kim J, Lee J, Gonzalez J, Fuentes-Duculan J, Garcet S, Krueger J . Proportion of CD4CD49bLAG-3 Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index. J Invest Dermatol. 2018; 138(12):2669-2672. DOI: 10.1016/j.jid.2018.05.021. View

11.

Kim J, Lee J, Kim H, Kameyama N, Nazarian R, Der E . Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. J Allergy Clin Immunol. 2021; 148(5):1281-1292. PMC: 8553817. DOI: 10.1016/j.jaci.2021.04.021. View

12.

Krueger J, Ferris L, Menter A, Wagner F, White A, Visvanathan S . Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015; 136(1):116-124.e7. DOI: 10.1016/j.jaci.2015.01.018. View

13.

Ortega C, Fernandez-A S, Carrillo J, Romero P, Molina I, Moreno J . IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009; 86(2):435-43. DOI: 10.1189/JLB.0109046. View

14.

Ascension A, Arauzo-Bravo M, Izeta A . The need to reassess single-cell RNA sequencing datasets: the importance of biological sample processing. F1000Res. 2022; 10:767. PMC: 8984215. DOI: 10.12688/f1000research.54864.2. View

15.

Guttman-Yassky E, Nograles K, Krueger J . Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011; 127(6):1420-32. DOI: 10.1016/j.jaci.2011.01.054. View

16.

Maggi L, Santarlasci V, Capone M, Peired A, Frosali F, Crome S . CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol. 2010; 40(8):2174-81. DOI: 10.1002/eji.200940257. View

17.

de Boer O, van der Loos C, Teeling P, van der Wal A, Teunissen M . Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem. 2007; 55(9):891-8. DOI: 10.1369/jhc.6A7119.2007. View

18.

Kim J, Krueger J . Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annu Rev Med. 2016; 68:255-269. DOI: 10.1146/annurev-med-042915-103905. View

19.

Lelios I, Cansever D, Utz S, Mildenberger W, Stifter S, Greter M . Emerging roles of IL-34 in health and disease. J Exp Med. 2020; 217(3). PMC: 7062519. DOI: 10.1084/jem.20190290. View

20.

Kim J, Oh C, Jeon J, Baek Y, Ahn J, Kim D . Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. J Invest Dermatol. 2016; 136(1):161-172. PMC: 4731034. DOI: 10.1038/JID.2015.378. View